Twenty-one paediatric patients (11 males and 10 females) received a CD34-selected partially matched related donor transplant for malignant (16 cases) and non-malignant conditions (five cases). The average cell dose was 11.13 ؋ 10 6 /kg. Fifteen of 16 patients with malignant conditions and one with non-malignant disease received total body irradiation plus cyclophosphamide. Three of 5 patients with non-malignant conditions and one with leukaemia, received busulphan plus cyclophosphamide. One patient with Fanconi anaemia received 100 mg/kg of cyclophosphamide. Fludarabine (25 mg/m 2 /day for 5 days) was administered prior to all these regimens. Additionally, anti-lymphocyte gamma-globulin (12.5 mg/kg/day) was administered from day ؊2 to day +2. Three (15%) patients failed to achieve complete chimaerism (CC). These patients received a second cell infusion. Two of them achieved CC. In the third patient, the percentage of donor cells was increased. The likelihood for engraftment was not related to the cell dose received. Acute graft-versus-host disease (GVHD) occurred in nine patients but only one developed GVHD Ͼgrade II. Eight patients developed active viral infections, which resolved after treatment. Patients receiving cell doses higher than our average had a significantly faster CD3 and CD4 cell recovery and experienced a lower incidence of viral infections. After 480 ؎ 255 days of median follow-up, 16/21 patients are alive and well and have CC. Three patients died of leukaemic relapse and a fourth from progression of his disease (adreno-leuko-dystrophy). We conclude that partially matched related donors are a feasible source of haemopoietic progenitor cells for transplantation for patients without matched familial or unrelated donors.
Haemopoietic progenitor transplantation (HPT) is the treatment of choice for a number of malignant and non-malignant conditions. In the last decade, its indications have been expanded to different genetic conditions where HPT can provide a functional improvement when other alternative therapies are not readily available. Unfortunately, the sources for haemopoietic progenitors have not increased to the same extent. The availability of donors is still a major concern, as it limits access for many patients to this form of treatment. Partially matched related donors (PMRD) are a possible alternative for paediatric patients, as almost every child has a potential haploidentical donor within his family.
PMRD have traditionally been considered a second-line source for haemopoietic progenitor cells. For example, the EBMT Paediatric Diseases Working Party only recommends PMRD in high risk acute myeloblastic leukaemia (AML) when no matched familial donor (MFD) or matched unrelated donor (MUD) is available. 1 This policy has its justification in the high rates of severe forms of graftversus-host disease (GVHD), graft failure and infectious complications that contribute to the high transplant-related mortality associated with this form of HPT. [2] [3] [4] [5] [6] [7] [8] [9] However, more recent reports have suggested otherwise. [10] [11] [12] [13] [14] [15] In most of these reports, the conditioning regimens consist of potent immunosuppressive combinations intended to increase immune tolerance. Unfortunately, these regimens also interfere with the post-transplant immune reconstitution, therefore increasing the risk of infectious complications. 5, 8, 9, 11 Fludarabine monophosphate is a relatively non-toxic agent that causes severe T cell immunosuppression by inhibiting adenosine deaminase. 16 This purine analogue is currently used to provide immune tolerance in other clinical settings. 17, 18 Its addition to a standard conditioning regimen 14 could reduce the tendency to rejection associated with PMRD HPT. In addition to fludarabine, the combination of CD34-positive selection and a lymphocyte-toxic gamma-globulin (anti-lymphocyte gamma-globulin (ALG) in our practice), 5, 9, 11, 12 could reduce the risk for severe forms of GVHD.
We present 21 sequentially treated paediatric patients who received CD34-purified HPT from PMRD. In all cases, the conditioning regimen consisted of a standard myeloabl-ative combination of radiotherapy and/or chemotherapy together with fludarabine and ALG.
Patients and methods
Our PMRD HPT programme started in February 1999. This programme is intended to make HPT accessible to all our patients without a MFD or MUD, who suffer from malignant or non-malignant conditions where transplantation is considered the treatment of choice. In all cases, written informed consent was obtained.
Twenty-one patients (11 males and 10 females) have been admitted to this programme to date. The median Ϯ standard deviation (s.d.) age at transplant was 8 Ϯ 4.02 years. The indications for HPT were malignant conditions in 16 cases and non-malignant diseases in five cases. These indications are detailed in Table 1 .
Patient number 7, initially diagnosed as suffering from idiopathic aplastic anaemia, received a HPT after total body irradiation plus cyclophosphamide. This child died of radiotherapy-related toxicity (involving skin, gut and lungs) at day +18. At that stage, she had fully engrafted and was Patient number 7, suspected of suffering from Fanconi anaemia, died at day +18 while being complete chimaeric and, therefore, she was excluded from further analysis. M = male; F = female; AML = acute myeloblastic leukaemia; ALL = acute lymphoblastic leukaemia; MDS = myelodysplastic syndrome; MHS = malignant haemophagocytic syndrome; CD40LD = CD40 ligand deficiency; ALD = adreno-leuko-dystrophy; CR = complete remission; P = parent; S = sibling; H = haploidentical; mm = mismatch; BuCy = busulphan plus cyclophosphamide; TBI+Cy = total body irradiation plus cyclophosphamide; HZV = herpes zoster virus; CMV = cytomegalovirus; EBV = Epstein-Barr virus; HSV 19 All patients received a full course of 5 days of fludarabine at standard doses (25 mg/m 2 /day) prior to all of the described regimens above. Additionally, equine ALG (12.5 mg/kg/day) was administered from day Ϫ2 to day +2. A minimum platelet count of 50 ϫ 10 9 /l was a prerequisite before ALG.
Additional measures common to all patients included the administration of anti-infection prophylaxis consisting of aciclovir, fluconazole and intravenous immunoglobulin (IVIG). Co-trimoxazole was administered starting by day +30 in all cases. Cyclosporin A (CsA) was administered as GVHD prophylaxis starting at day Ϫ1. The policy was to withdraw CsA by day +30 as long as no signs of GVHD were present. Finally, G-CSF was administered starting by day +8 in all cases.
Transplantation
All patients received a peripheral blood HPT from a PMRD, after CD34 /kg (mean 7.01). Except for patients 12 and 16 (whose donors were siblings), the rest of the patients received grafts from parental donors. Donor-recipient sex mismatch was present in 11 cases. The CD34 cell doses for each patient and the degree of mismatch are detailed in Table 1 .
Monitoring
While inpatients, all children had daily monitoring of their blood counts, as well as electrolytes, transaminases and bilirubin. Plasma CsA levels were checked three times weekly and cytomegalovirus (CMV) status was assessed on a weekly basis by polymerase chain reaction (PCR) in peripheral blood. After discharge, all these parameters were assessed weekly.
The chimaeric status was assessed on a monthly basis by fluorescence in situ hybridisation (FISH) in sex-mismatched pairs and DNA polymorphisms in matched donorrecipient pairs. Patients failing to achieve CC 1 month post transplant, received a second CD34 cell dose from the same donor, after a complete course of fludarabine (25 mg/m 2 /day for 5 days starting 14 days prior to reinfusion) and one single dose of anti-thymocyte gammaglobulin (ATG) The ATG was administered the same day that the cells were infused.
Immune recovery was monitored by flow cytometry every month whenever possible. The panel of monoclonal antibodies used in each assessment included CD3 (as well as CD4 and CD8), CD56 and CD19 as representative for T lymphocytes, natural killer (NK) cells and B lymphocytes, respectively.
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Data analysis
The incidence of major complications (incomplete chimaerism, viral infections, GVHD and relapse) was analysed depending on the sort of conditioning (radiotherapy/no radiotherapy), donor-recipient sex mismatch, and CD34 cell dose administered by the chi-square test. The CD34 cell dose was previously transformed into two different qualitative variables (cell dose higher/lower than the median and cell dose higher/lower than the mean cell dose). The median and the average cell doses were chosen as cutoff points for comparison because both of them represent achievable cell doses in clinical practice.
Finally, haemopoietic recovery, as well as recovery of the different lymphoid subsets, were analysed depending on the same variables as above, by a Mann-Whitney U test at each point of observation.
Results
Haemopoietic recovery
Engraftment was seen in all patients. Most patients (19/21) recovered neutrophils within the first 15 days after transplant. The median time for neutrophil recovery (absolute neutrophil count у0.5 ϫ 10 9 /l) was 12 Ϯ 7.21 days and 19.5 Ϯ 7.13 days for platelets (platelets у50 ϫ 10 9 /l). No significant differences were found between patients receiving different CD34 cell dosages, conditioning schedules or grafts from sex matched or mismatched donors.
Three patients (patient numbers 5, 9 and 15) failed to achieve CC. They received a second CD34 cell dose from the same donor, after fludarabine and ATG. The description of these three cases is as follows: Patient number 5 had 90% donor cells at day +30, together with evidence of progression of her condition (malignant haemophagocytic syndrome). She received 8.25 ϫ 10 6 CD34 cells/kg after fludarabine, ATG and total lymphoid irradiation. She remains alive and well and CC, 639 days after transplant. Patient number 9 was found to have 30% of donor cells at day +60. Soon after transplant, he had received gancyclovir as treatment for CMV-related haemorrhagic cystitis. He received 7.0 ϫ 10 6 CD34 cells/kg after fludarabine and ATG. Unfortunately, he died after rapid progression of his disease (adreno-leuko-dystrophy), 81 days after reinfusion. By day +60 post reinfusion, he had 70% donor cells. Finally, patient number 15, with 90% of donor cells at day +60, was reassessed in subsequent days and found to be rejecting the graft. This last patient had received minimal conditioning for Fanconi anemia (see above). She received 22.01 ϫ 10 6 CD34 cells/kg after fludarabine, ATG and 5 days of high-dose steroids (500 mg/m 2 /day) on the same days that fludarabine was given. She remains alive and well and CC, 418 days after transplant.
Interestingly, only three patients in this series received megadoses (cell dose Ͼ20 ϫ 10 6 CD34 cells/kg). One of them (patient number 15) failed to achieve CC. The incidence of incomplete chimaerism was significantly higher in patients not receiving radiotherapy (P Ͻ 0.04). The chimaeric status does not seem to be influenced by CD34 cell dose or the sex match between donor and recipient.
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Lymphoid recovery
Overall, we found a delayed lymphoid recovery. Figure 1 shows the median absolute CD3, CD19 and CD56 counts at different moments after transplant. The delay in lymphoid recovery was particularly evident in the CD3 subset. In most patients, the presence of CD3 cells became evident in the second month after transplant, but they only reached 0.2 ϫ 10 9 /l within the 4th month. Statistical analysis of these data showed that, while the type of conditioning received did not exert any influence on the immune recovery, the CD34 cell dose was a determining factor. Patients receiving cell doses higher than our median, had significantly higher counts of both CD3 (P Ͻ 0.05) and CD4 (P Ͻ 0.03) lymphocytes by day +60. In patients receiving doses higher than our mean, the CD4 cell counts remained significantly higher (P Ͻ 0.05) by day +180.
Complications
Acute GVHD was clinically evident in nine patients (Table 1 ), but only six of them required treatment. It is noteworthy that only one patient developed GVHD Ͼgrade II. Chronic GVHD was seen in four patients. The incidence of both was not influenced by the CD34 cell dose, the type of conditioning received or the presence of sex mismatch. and 19 (asymptomatic positive PCR)), and Epstein-Barr virus (EBV) in one case (patient 13). This last case is of special interest, as it appeared in the 3rd month after transplant and behaved as infectious mononucleosis. This episode resolved after the CsA this patient was having as treatment for GVHD was withdrawn. Interestingly, 14/21 donor-recipient pairs were positive for CMV prior to transplant.
Eight of 14 patients receiving less than the average CD34 cell dose developed active infections, whereas none of the patients receiving cell doses higher than the average suffered this complication (P Ͻ 0.05).
The administration of radiotherapy did not seem to have any influence on the incidence of active viral infections. No fungal infections were seen.
Clinical outcome and survival
The overall survival after 480 Ϯ 255 days of median follow-up is 71%. Among the patients with malignant conditions, three have relapsed. Two of them suffered from T cell ALL (they were the only ones with this diagnosis in our series) and the third patient suffered from common ALL in third complete remission (CR). Due to the lack of homogeneity of our series, no further analysis was performed. Consequently, 13/16 (81.3%) patients are alive, well and in CR. Within the group with non-malignant conditions, patient number 9 died from rapid disease progression (adreno-leuko-dystrophy) despite transplant and patient number 7 died of TBI-related toxicity. The rest of patients (60%) remain alive and well with CC.
Overall, the transplant-related mortality was 4.8%. However, the only death observed was most probably due to inappropriate conditioning (patient number 7, with Fanconi anaemia which did not present with the habitual chromosomal breakage findings) rather than to receiving a mismatched graft.
Discussion
PMRD HPT have been reported to have a high incidence of graft failure and GVHD. Most approaches designed to override these complications involve a combination of both ex vivo T cell depletion of the graft plus a final in vivo lymphoid depletion. 5, [7] [8] [9] [10] [11] [12] These immunosuppressive schedules could be partly responsible for the increased incidence of opportunistic infections reported in PMRD HPT. The most relevant reports on mismatched transplantation are detailed in Table 2 , together with their complications and clinical outcomes.
Our approach to HPT from PMRD is to combine the effects of fludarabine, ALG and CD34 positive selection. Fludarabine is currently used in the conditioning of miniallografts, 17, 18 where the induction of immune tolerance seems to play a key role in the success of the transplant. Its addition to a standard conditioning regimen might increase the tolerance in the recipient to accept an otherwise incompatible graft. 14 The administration of ALG prior to transplant is intended to reduce the T cells in the recipient to a minimum (to increase the acceptability of the graft), while its administration after transplantation is aimed to provide a further reduction in the T cells present in the graft. The first difficulty reported by different groups currently performing PMRD HPT is to achieve engraftment. The administration of a megadose inoculum of highly purified CD34 cells is a possible strategy to override this problem. 20, 21 This approach is based on the facilitating effect provided by the 'veto' cells within the graft. 21 However, different reports show this approach still results in a high percentage of graft failures. In the series reported by Peters et al, 9 the incidence of graft failure is close to 29%, after administering a median of 21.5 ϫ 10 6 CD34 cells/kg. Handgretinger et al 12 reported a 20% failure rate with grafts containing an average number of 14.2 ϫ 10 6 CD34 cells/Kg. A possible explanation for these divergences may be that the cell dose required for achieving this effect is too high to be achieved from human donors. 21 It appears therefore that additional immunosuppression is required to achieve engraftment. A recent study reported by Passweg et al 5 supports this idea as, for a given CD34 cell dose, it is the complementary conditioning (ATG and OKT3 in this series) that determines the likelihood for sustained engraftment.
Three (15%) of our patients failed to achieve CC. In patient number 15, this could be considered a consequence of deficient conditioning. Patient number 5 developed signs suggesting progression of her malignant haemophagocytic syndrome. Finally, patient number 9 suffered secondary graft failure related to CMV reactivation and treatment with ganciclovir. The differences we have observed, using mainly three loci-mismatched donors, are probably due to a combination of factors.
The CD3 cell dose we administered was lower than that reported by other groups (Table 2 ). This might increase the likelihood of some T cell subsets, important for engraftment, 22 being administered to the recipient. On the other hand, our mean cell dose (11.13 ϫ 10 6 CD34 cells/kg) is lower than in the studies discussed above. We have not found significant differences, in terms of engraftment, between patients receiving doses higher or lower than our average, suggesting that the combination of fludarabine and ALG plus a standard myeloablative regimen is largely responsible for the low incidence of graft failure we have observed.
Although we also found that patients receiving radiotherapy have a lower incidence of incomplete chimaerism, we believe this result to be of doubtful significance, as the distribution of patients receiving radiotherapy is not homogeneous (most patients with non-malignant conditions did not receive radiotherapy). Although a stable graft can be achieved with chemotherapy alone, 10 similar studies have reported TBI as an independent factor facilitating engraftment in this modality of transplant. Donor lymphocyte infusions (DLI) are a possible strategy for the correction of incomplete chimaerism in MFD transplants. 23 Although DLI from haploidentical donors has been used in other clinical settings, 24 this procedure can lead to severe forms of GVHD. 6 Our approach to this situation is to administer a second CD34 cell dose from the same PMRD after fludarabine and one single dose of ATG.
Since ATG and ALG are obtained from different sources, switching from ALG to ATG may widen the spectrum of lymphoid subsets targeted by these immunoglobulins, thus reducing the likelihood of rejection. Two of three patients receiving a second cell infusion remain in CC more than 1 year after transplant. Although patient number 9 did not achieve CC, the percentage of donor cells increased to 70%, supporting the use of this approach to escalate the percentage of allogeneic cells.
Functional immune reconstitution after purified mismatched HPT has been recently studied in a murine model. 25 Even when full numerical recovery has been achieved, several functional deficits can be observed. These deficits are severe in fully mismatched grafts, suggesting that degree of mismatch is a contributing factor to the high incidence of opportunistic infections, particularly of viral origin (including development of EBV-related malignant lymphoproliferative syndromes 26 ), that occurs in these patients.
We have seen a high incidence (8/21) of viral infections in these patients. However, despite the immunosuppressing schedule that these patients received, we only saw three cases of CMV reactivation in 14 CMV-positive donorrecipient pairs. Interestingly, Bunjes et al 11 reported a series of 10 haploidentical transplants in adults in the year 2000 where all patients with positive pre-transplant serology for CMV developed viremia despite prophylactic gancyclovir.
In addition to this observation, patient number 13 developed infectious mononucleosis, which resolved after CsA was withdrawn. It appears, therefore, that there is a fast recovery of T cell activity capable of limiting viral spread.
In our experience, CD34 cell dose influences immune recovery.
Finally, and most interestingly, doses higher than our mean allowed faster CD3 and CD4 recovery and significantly reduced the incidence of viral reactivation.
As discussed above, the CD3 cell dose which we have administered to our patients is higher than in other studies. Undoubtedly, this would potentially increase the possibility of developing GVHD. In our experience, 20% patients required treatment, but only 5% developed GVHD Ͼgrade II. These figures are probably influenced by the use we make of CsA, as we currently administer this immunomodulator while acute GVHD is more likely to occur, but we withdraw it when viral infections are more likely to occur. Some groups do not currently administer CsA as GVHD prophylaxis 5, 11, 12, 15 due to the extensive lymphoid depletion they perform. Finally, according to our results, CD34 cell dose does not seem to influence the incidence of GVHD.
Conclusion
Overall, doses as high as 20 ϫ 10 6 /kg, previously reported as desirable target 9, 12, 15, 20, 21 (but difficult to achieve in clinical grounds), do not seem strictly necessary to perform a HPT safely. Indeed, only three of our patients received this range of doses, one of which resulted in incomplete chimaerism. In our experience with commonly achieved doses, 85% patients engrafted. Two more patients achieved CC after a second cell infusion. Although cell dose seems important to accelerate immune recovery and reduce the incidence of viral infections, these effects can be achieved with doses higher than 11 ϫ 10 6 /kg (not necessarily with CD34 megadoses).
Although we have only observed 3/16 relapses in the group of patients with malignant conditions (all of them in high risk patients), the design of our study does not allow us to assess any potential for a graft-versus-leukaemia (GVL) effect. It has been postulated that donor NK cell alloreactivity might play a role in the GVL effect. Briefly, the donor NK cells would not recognise recipient MHC allotypes and would, therefore, attack host cells. This type of immune reaction is exclusive to mismatched transplants. 21 Moreover, it has been shown that the NK cells, arising from donor stem cells once the engraftment has been achieved, still maintain this reactivity. 27 These cells can lyse AML and CML cells in vitro. 21 The low reactivity they present against ALL cells might be explained by the low expression of LFA-1 that these cells have. 21 Overall, it appears that the use of mismatched donors could enhance the potential for a GvL effect in conditions of myeloid lineage, even when T cells in the graft have been depleted.
Since we have observed a very low transplant-related mortality, the presence or absence of GVL seems to be the only argument for maintaining the preference for MUD transplants. Certainly, in terms of time required to find a feasible donor, PMRD are an advantageous source for stem cells. 28 In conclusion, our results suggest that patients with no MFD or MUD can safely receive a HPT from a PMRD. The combination of CD34 selection, fludarabine and ALG, allows sustained engraftment without a high risk of severe GVHD. Patients failing to achieve complete engraftment can safely receive further CD34 cell doses after minimal conditioning. An inoculum of at least 11 ϫ 10 6 CD34 cells/kg, allows faster CD3 and CD4 recovery and reduces the incidence of viral infections. We believe that prospective comparative studies should be carried out in order to determine the potential for a GVL effect with this form of transplantation, in comparison with MUD transplants.
